



Press Release

Oxford Gene Technology appoints Dr David Owen to the Board

Oxford, October 4, 2005. Oxford Gene Technology (OGT) is delighted to announce the appointment of Dr David Owen to the OGT Board as a Non-Executive Director.

After graduating with a PhD in pharmacology, David worked in R&D in the pharmaceutical industry for 20 years (Sandoz and SmithKline and French). He went on to lead technology driven licensing agreements for SmithKline and French as Group Director for Compound and Technology Acquisitions. In 1990 he joined the MRC as CEO of MRC Technology, and led technology transfer activities in patenting, licensing technologies, creating new “start-up” companies and generation of revenues.

In June 2001 David was awarded the OBE for services to medical research and technology transfer.

David is currently Non-Executive Chairman of Abcellute Ltd. and the Cardiff Partnership Fund, Co-Chairman of EMBL Enterprise Management, GmbH, in Heidelberg and is a past President of the Association of European Science and Technology Transfer Professionals.

David said, “I am delighted and very flattered to be invited to participate in the business of OGT. The Company’s leading technologies are fundamental tools in many facets of molecular biology research and thereby facilitate key advances in bioscience knowledge and understanding. I look forward to joining fellow Directors in building on the current success of OGT and to help develop the Company further.”

Professor Sir Ed Southern, OGT’s Chairman, said, “I am pleased to welcome David to the OGT Board. He has had a distinguished career in pharmaceutical research and technology transfer and will bring a wealth of experience.”

About OGT

Oxford Gene Technology (OGT) is a privately owned company founded in 1995 by Professor Sir Edwin Southern. The mission of the company is to develop advanced molecular tools for biologists and to make them widely available through licensing and service activities. The key business areas of OGT include

- licensing which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
- a services business which provides a flexible and cost-effective, customised DNA microarray service covering a range of applications and offers specialist support to assist customers with every aspect of their research.
- Tridend, which is developing 'mass tags' to enhance the amount of information that researchers can generate from mass spectrometry experiments in proteomics and genomics
- Oxamer, which is generating novel array formats based on electrochemical deposition methods for use in life science and diagnostics

OGT's intellectual property covers four general areas that are relevant to the biological sciences; these incorporate microarrays, genomics, proteomics and electrochemistry.

<p>Oxford Gene Technology IP Limited Begbroke Business and Science Park, Sandy Lane, Yarnton, Oxford, OX5 1PF UK Tel: +44 (0) 1865 856 340 Fax: +44 (0) 1865 379 433 Email: licensing@ogt.co.uk Web: www.ogt.co.uk</p>	<p>© 2005 kdm communications limited Editorial contact for further information or follow-up Sarah Withington at kdm communications limited, Bedford, UK Tel. +44 01234 210555 Fax: +44 01234 342397 email: ideas@kdm-communications.com</p>
--	--